Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

HitGen Forms Dermatology Lead Discovery Partnership with Spain's Almirall

publication date: Mar 25, 2019

HitGen of Chengdu will collaborate with Almirall. a Barcelona dermatology company, to identify novel small molecule leads for targets of interest. HitGen will search its DNA-encoded library technology platform, which is currently estimated to contain 400 billion leads, to discover, synthesize and screen the leads. Almirall asked HitGen to discover leads for new targets associated with atopic dermatitis. HitGen will receive upfront payments, and be eligible for milestone payments from Almirall, though specific financial details were not disclosed. More details....

Stock Symbol: (SPA: ALM)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.